Drug intelligence / Profile preview

uropolypeptide

Development stage: Unknown
Modality: Small Molecules, Peptides
Administration: Injection

Overview

Uropolypeptide is a non-cytotoxic biological agent derived from the fresh urine of healthy individuals. It is primarily used in combination chemotherapy for the treatment of advanced breast cancer and non-small cell lung cancer. The drug is composed of various natural active ingredients, including hippuric acid, phenacetylamino piperidinedione, phenylacetic acid, indoleacetic acid, phenacetylglutamine, indoleacetic acid, and small molecule peptides. Beyond its role in oncology, uropolypeptide has also shown potential in treating skin scars by modulating fibroblast activity.

Other names: 尿多酸肽Uropolyacitide

Beyond the preview

Go deeper on uropolypeptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on uropolypeptide.

Explore the full profile